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 اإلستجابة املتأخرة للعالج يف طفل حديث الوالدة مصاب
مبرض الجنرهانز هيستيوسيتوزيس
تقرير حالة ومراجعة الألدبيات
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abstract: Langerhans cell histiocytosis (LCH) is a rare proliferative disorder of the Langerhans cells, which are 
part of the mononuclear phagocytic system. The disorder varies in terms of the extent of the disease, its natural 
course and patient outcomes. While skin rashes are a common presentation of neonatal LCH, other systems or 
organs may also be involved. Delays in the diagnosis of neonatal LCH may occur due to its non-specific presentation 
and a lack of awareness of the condition among doctors. We report a two-month-old male neonate who presented 
to the Chacha Nehru Bal Chikitsalya hospital, New Delhi, India, in 2016 after the onset of pulmonary symptoms. 
He had been noted to have a generalised rash which had progressively worsened from 15 days of age. Following a 
skin biopsy and chest imaging, he was diagnosed with multisystem LCH with risk organ involvement. There was a 
delayed response to combined chemotherapy with no major side-effects.
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البلعمة وحيدات  امللخ�ص: مر�س الجنرهانز هي�ستيو�سيتوزي�س هو ا�سطراب تكاثري نادر خلاليا الجنرهانز، والتي هي جزء من نظام 
النوى. ويختلف املر�س من حيث مدى انت�ساره، وتدرجه الطبيعي ونتائج املر�سى. و يف حني اأن الطفح اجللدي هو عر�س �سائع للمر�س 
يف حديثي الوالدة، ميكن اأي�سا اأن ت�سمل اأعرا�س املر�س اأع�ساء اأو اأجهزة اأخرى. قد يحدث تاأخرييف ت�سخي�س املر�س يف حديثي الوالدة 
ب�سبب بدايته باأعرا�س غري حمددة واأي�سا عدم وجود الوعي الكايف باملر�س واأعرا�سه بني االأطباء. هذا تقرير حالة لذكرحديث الوالدة 
يبلغ �سهرين من العمر قدم اإىل م�ست�سفى ت�سات�سا نهرو بال �سيكيت�سااليا، نيودلهي، الهند، يف عام 2016 بعد ظهور االأعرا�س الرئوية عليه. 
وقد لوحظ عليه اأي�سا طفح جلدي عام، تفاقم تدريجيا من 15 يوما من العمر. وقد مت اأحذ خزعة من اجللد والت�سوير ال�سدري، مت ت�سخي�سه 
الكيميائي  للعالج  متاأخرة  ا�ستجابة  هناك  كانت  املختلفة.  اجل�سم  اأع�ساء  ا�سابة  خطر  وجود  مع  هي�ستيو�سيتوزي�س  الجنرهانز  مبر�س 
املركب مع عدم حدوث اأي اآثار جانبية كبرية.
الكلمات املفتاحية: مر�س الجنرهانز هي�ستيو�سيتوزي�س؛ التهاب اجللد الدهني؛ ت�سارع النف�س؛ فقر الدم؛ ر�سيع؛ تقريرحالة؛ الهند.
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Langerhans cell histiocytosis (LCH) is a very rare disease resulting from the clonal proliferation of Langerhans cells in the mono-
nuclear phagocytic system.1 The disorder can occur 
at any age and may be either completely benign and 
self-resolving or fatal and refractory. Clinically, the 
presentation varies depending on whether the patient 
has single-system (i.e. involvement of only one organ 
or system) or multisystem (i.e. involvement of two or 
more organs or systems) LCH.1 The involvement of 
the liver, spleen, bone marrow or lungs is classified 
as risk organ (RO) involvement, as this may adversely 
affect patient outcomes.2
Neonatal LCH is believed to be under-reported 
with an incidence of slightly over 1 per million 
newborns.3 Nearly all cases present within the first 
four weeks of life, most commonly with single-
system LCH with spontaneous remission (also known 
as Hashimoto-Pritzker disease or congenital self-
healing LCH).4 However, a thorough investigation 
of most single-system neonatal LCH cases will show 
involvement other sites; moreover, multisystem LCH 
in neonates has a less favourable prognosis compared 
to those of other age groups.3 Similarly to older 
children, the optimal treatment option for infants with 
LCH is combination chemotherapy as per the 2009 
Histiocyte Society guidelines for LCH evaluation and 
treatment.2 This report describes a case of neonatal 
multisystem LCH with RO involvement treated 
successfully with combined chemotherapy as per the 
2009 Histiocyte Society guidelines.2
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Case Report
A two-month old male neonate presented to the 
Chacha Nehru Bal Chikitsalya hospital, New Delhi, 
India, in 2016 with tachypnoea over the past seven 
days and a progressive generalised rash of one and a 
half months’ duration. The baby was the first child of 
nonconsanguineous healthy parents. The antenatal 
course had been uneventful and he was born at term 
via normal vaginal delivery. At birth, he weighed 
3.4 kg with no adverse perinatal events. The neonate 
was breastfed exclusively. Shortly after birth, the 
mother noted a rash on the infant’s scalp which 
rapidly spread over the whole body over the next 
15 days. Initially, the baby was treated for cradle cap 
after consultation with a paediatrician; however, 
as the skin lesions increased, he was referred to a 
dermatologist who diagnosed him with extensive 
seborrhoeic dermatitis. Topical medications were 
prescribed but were ineffective. There was no medical 
history of fever, coughing, lethargy, poor feeding, 
cyanosis, jaundice, abdominal distention, vomiting, 
loose stools, seizures or bleeding. However, there was 
a history of ear discharge and increased urine output.
At presentation, the child had tachypnoea 
and mild chest retractions but maintained normal 
oxygenation in room air. There were extensive 
papulonodular lesions with crusting over his whole 
body, although the mucosal surfaces were unaffected 
[Figure 1A]. There was no evidence of pallor, icterus or 
lymphadenopathy. A systemic examination revealed 
hepatomegaly and fine crepitations in both sides of 
the chest. Blood test results revealed mild microcytic 
hypochromic anaemia and hepatitis [Table 1]. A 
peripheral smear showed microcytic hypochromic red 
blood cells with anisopoikilocytosis and no abnormal 
cells. Bilateral diffuse lung parenchymal opacities with 
cysts were observed on a chest X-ray, with computed 
tomography (CT) confirming the presence of diffuse 
cystic lesions in both lungs [Figure 2]. An ultrasound 
of the liver indicated a heterogeneous echotexture 
with peri-portal echogenicity. A skin biopsy revealed 
 
Figure 1: Photographs of a two-month-old male neonate (A) at presentation, with extensive papulonodular lesions and 
crusting over the whole body and a seborrhoea-like rash over the scalp, (B) after six weeks of chemotherapy, with limited 
resolution of the lesions and hypopigmented macules, and (C) after six months of therapy, with very few remaining 
hyperpigmented lesions and fine scaling.
Table 1: Blood investigation results of a two-month-
old male neonate with pulmonary symptoms and a 
generalised whole-body rash
Investigation Result
Hb in gm/dL 10.5 
WBC per mm3 10,600
Neutrophils in % 76
Lymphocytes in % 19
Monocytes in % 4
Eosinophils in % 1
Platelet count per mm3 301 x 103
Total bilirubin in g/dL 0.9 
Conjugated bilirubin in g/dL 0.4
AST in U/L 115 
ALT in U/L 213
Total protein in g/dL 5.9
Albumin in g/dL 3.5
ALP in U/L 81
GGT in U/L 115
Urea in mg/dL 28
Creatinine in mg/dL 0.3
Hb = haemoglobin; WBC = total leukocyte count; AST = aspartate 
transaminase; ALT = alanine transaminase; ALP = alkaline 
phosphatase; GGT = gamma glutamyl transferase.
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Discussion
The differential diagnosis of a neonatal skin rash 
includes congenital infections (e.g. cytomegalovirus, 
rubella, toxoplasma, herpes simplex virus or syphilis 
infections), seborrhoeic dermatitis, LCH, dissemi-
nated candidiasis, neonatal varicella, neonatal 
pustular melanosis and mastocytosis.1,5 This report 
describes a case of neonatal multisystem LCH with 
RO involvement which was initially misdiagnosed as 
seborrhoeic dermatitis and only accurately diagnosed 
following the onset of pulmonary symptoms. 
Although the presentation in this case was similar 
to other cases described in the literature, there was a 
delay of approximately one and a half months before 
the correct diagnosis was established.3,4 According to 
data from a European LCH study group, only 32.7% 
of neonatal LCH cases were diagnosed during the 
neonatal period.3 In an American cohort, the mean age 
at diagnosis was three and a half months for neonatal 
LCH cases, with initial misdiagnoses often including 
psoriasis and chronic dermatitis.6 
As the type and characteristics of skin lesions 
in neonatal LCH are not predictive of the extent 
of disease involvement, a thorough multiorgan 
evaluation is indicated for all patients.6,7 Data from 
a European LCH study group indicated that most 
neonatal LCH cases had multisystem involvement 
(59%), with skin lesions being the most common 
initial presentation; in addition, 5.5% of multisystem 
cases had dyspnoea.3 As such, dyspnoea secondary to 
lung involvement could indicate an advanced disease 
state, as seen in the present case. Park et al. reported 
that skin lesions were also the most common initial 
presentation among six neonatal LCH cases in Korea 
(83.3%).7 In a case series of 19 neonatal LCH patients 
with dermatological presentations in the USA, Stein 
et al. noted that 68% were male and 63% had 
multisystem involvement.6 The most common skin 
lesions observed were erythematous vesicopustules 
infiltration by Langerhans cells with cluster of 
differentiation (CD) 1a positivity, confirming the 
diagnosis of LCH [Figure 3]. A skeletal survey, bone 
marrow examination and brain magnetic resonance 
imaging ruled out any skeletal, bone marrow or central 
nervous system involvement.
Following the diagnosis, the neonate was treated 
with daily prednisolone and weekly vinblastine at 
modified doses as per the 2009 Histiocyte Society 
guidelines.2 However, although the lesions began to 
atrophy and depigment after six weeks, new lesions 
began to appear, some of which were deeply ulcerated 
[Figure 1B]. Due to worsening dyspnoea, the child was 
admitted to hospital as an inpatient for monitoring. 
As he had demonstrated an incomplete response to 
the initial treatment, prednisolone and vinblastine 
were continued for another six weeks. Following this, 
positron emission tomography/computed tomography 
indicated that the disease was non-active [Figure 4]; as 
such, continuation therapy was initiated. At the time of 
writing, after a total of six months of therapy, the child 
was asymptomatic and appeared to be thriving. The 
pneumatoceles had disappeared completely, with only a 
few hyperpigmented skin lesions remaining [Figure 1C]. 
As per the 2009 Histiocyte Society guidelines, another 
12 months of treatment were subsequently planned.2
 
Figure 3: A: Haematoxylin and eosin (H&E) stain of a punch biopsy at x200 magnification showing diffuse replacement 
of the superficial dermis by enlarged mononuclear cells (arrow). B: H&E stain at x400 magnification showing mono-
nuclear cells with abundant eosinophilic cytoplasm and kidney-shaped grooved folded nuclei (arrow) and fine vesicular 
chromatin and inconspicuous nucleoli. C: Immunohistochemistry stain at x400 magnification showing neoplastic 
Langerhans cells immunopositive for cluster of differentiation 1a (arrow).
 
Figure 2: A: Chest X-ray of a two-month-old male 
neonate with pulmonary symptoms and a generalised 
whole-body rash showing bilateral diffuse lung 
parenchymal opacities with cysts. B: Computed 
tomography in the chest axial view showing cysts of 
variable sizes involving both lungs.
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(53%), often with crusting, followed by eczematous 
scaling lesions in a seborrhoea-like distribution (37%) 
and oral mucosal lesions (20%).6 In contrast, the 
present patient had a seborrhoea-like skin rash without 
any mucosal involvement.
An accurate diagnosis of LCH requires either a 
histopathological examination of the involved tissue 
to demonstrate the presence of pathognomonic 
CD1a- and/or CD207-positive Langerhans cells or 
an electron microscopy study to identify Birbeck 
granules.1 However, a recent case report by Kumar 
et al. suggests that fine-needle aspiration cytology 
may also be effective in diagnosing LCH, alleviating 
the need for an invasive biopsy.8 Lung involvement 
in LCH has a variable appearance on chest CT scans, 
ranging from small peribronchiolar nodular opacities 
to multiple irregularly-shaped cysts.1 In the current 
case, the CT findings were pathognomonic, showing 
cysts of variable size in both lungs.
While a few cases of multisystem LCH have 
been reported to resolve spontaneously, this is very 
rare; only 8% of multisystem LCH cases reported 
by the European LCH study group, all without RO 
involvement, experienced complete resolution without 
systemic therapy and the five-year survival rate for 
multisystem LCH cases was 57%.3 Among the six 
Korean neonatal LCH cases, the probability of survival 
at 12 years was 50%.7 In an American cohort, survival 
was 16% with a variable follow-up period.6
Combination chemotherapy is the first line of 
treatment for LCH cases.2 The reactivation rate falls 
from 54% to 37% after treatment is prolonged from 
six to 12 months.9 However, patients frequently 
develop various disease- and treatment-related 
complications, including diabetes insipidus, hearing 
impairments and liver fibrosis; as such, it is 
recommended that all patients be monitored for at 
least five years after the end of therapy for related 
complications and disease recurrence.1
Conclusion
This report describes a case of neonatal multisystem 
LCH with RO involvement. In order to avoid a 
delayed diagnosis of neonatal LCH, paediatricians 
should become more familiar with this rare disorder. 
In addition, a thorough multiorgan evaluation is 
warranted in all cases of neonatal LCH with cutaneous 
presentations in order to rule out RO involvement. 
Use of the 2009 Histiocyte Society guidelines is 
recommended for the successful management of 
infants with LCH.
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Figure 4: Positron emission tomography/computed tomography showing no metabolically active disease in a two-
month-old male neonate presenting with pulmonary symptoms and a generalised whole-body rash following 12 weeks 
of treatment for multisystem Langerhans cell histiocytosis.
